Physician profile
Gabor Varju
NPI 1235342999
$10,058.28
in general payments reported to CMS, 2019-2025
29 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $1,612 · 2021: $1,085 · 2022: $821 · 2023: $1,247 · 2024: $855 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098 · Travel and Lodging: $1,118 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.90 |
| Travel and Lodging | $1,117.96 |
| Education | $156.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,506.65 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,676.67 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,335.06 | 2019-2025 | Ofev, Jascayd |
| Intuitive Surgical, INC. | $1,117.96 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $623.70 | 2021-2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $510.48 | 2019-2025 | Xolair |
| Philips North America LLC | $418.34 | 2019-2022 | |
| Grifols USA, LLC | $324.58 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genzyme Corporation | $302.78 | 2019-2025 | |
| Mylan Specialty L.P. | $226.68 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $148.38 | 2019-2025 | Dupixent |
| Viatris Specialty LLC | $126.23 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $98.36 | 2019-2025 | Winrevair |
| Sanofi-Aventis U.S. LLC | $96.95 | 2023 | |
| Insmed, INC. | $86.32 | 2019-2025 | Arikayce |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $64.88 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $52.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.74 | 2023-2025 | Glassia |
| Pulmonx Corporation | $41.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.26 | 2019 | |
| United Therapeutics Corporation | $36.28 | 2021-2024 | Tyvaso |
| Harmony Biosciences LLC | $32.02 | 2020-2021 | |
| Advanced Respiratory, INC | $31.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.80 | 2019-2021 | |
| Circassia INC. | $19.93 | 2019 | |
| Vivus LLC | $17.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.16 | 2019 | |
| Pfizer INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabor Varju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.